Next Article in Journal
A Review on Toxic and Harmful Algae in Greek Coastal Waters (E. Mediterranean Sea)
Next Article in Special Issue
Shiga Toxin Is Transported into the Nucleoli of Intestinal Epithelial Cells via a Carrier-Dependent Process
Previous Article in Journal
The Zinc-Dependent Protease Activity of the Botulinum Neurotoxins
Previous Article in Special Issue
The Role of Lymphostatin/EHEC Factor for Adherence-1 in the Pathogenesis of Gram Negative Infection
Article Menu

Export Article

Open AccessReview
Toxins 2010, 2(5), 998-1018; doi:10.3390/toxins2050998

Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives

Institute for Biological Sciences, National Research Council of Canada, 100 Sussex Drive, Ottawa, Ontario, K1A 0R6, Canada
This is NRC publication number 42534.
*
Author to whom correspondence should be addressed.
Received: 26 March 2010 / Revised: 29 April 2010 / Accepted: 5 May 2010 / Published: 7 May 2010
(This article belongs to the Special Issue Enterotoxins)
View Full-Text   |   Download PDF [279 KB, uploaded 7 May 2010]   |  

Abstract

Therapeutic agents targeting bacterial virulence factors are gaining interest as non-antibiotic alternatives for the treatment of infectious diseases. Clostridium difficile is a Gram-positive pathogen that produces two primary virulence factors, enterotoxins A and B (TcdA and TcdB), which are responsible for Clostridium difficile-associated disease (CDAD) and are targets for CDAD therapy. Antibodies specific for TcdA and TcdB have been shown to effectively treat CDAD and prevent disease relapse in animal models and in humans. This review summarizes the various toxin-specific antibody formats and strategies under development, and discusses future directions for CDAD immunotherapy, including the use of engineered antibody fragments with robust biophysical properties for systemic and oral delivery. View Full-Text
Keywords: Clostridium difficile; Clostridium difficile-associated disease; toxin; antibody; single-domain antibody; neutralization; therapy Clostridium difficile; Clostridium difficile-associated disease; toxin; antibody; single-domain antibody; neutralization; therapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Hussack, G.; Tanha, J. Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives. Toxins 2010, 2, 998-1018.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top